血友病治療薬の世界市場:種類別、地域別

◆英語タイトル:Hemophilia Therapeutics Market by Type and Geography - Forecast and Analysis 2020-2024
◆商品コード:IRTNTR41186
◆発行会社(リサーチ会社):Technavio
◆発行日:2020年2月4日
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Global Hemophilia Therapeutics Market 2020-2024
Technavio has been monitoring the global hemophilia therapeutics market and it is poised to grow by USD 4.19 bn during 2020-2024, progressing at a CAGR of 6% during the forecast period. Our reports on global hemophilia therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing number of initiatives to create awareness about hemophilia.
In addition, r&d of novel strategies to develop therapeutics is anticipated to boost the growth of the global hemophilia therapeutics market as well.

Market Segmentation

Technavio’s global hemophilia therapeutics market is segmented as below:
TypeHemophilia A Hemophilia B Hemophilia CGeographic segmentationNorth America Europe Asia ROW
Key Trends for global hemophilia therapeutics market growth

This study identifies r&d of novel strategies to develop therapeutics as the prime reasons driving the global hemophilia therapeutics market growth during the next few years.

Prominent vendors in global hemophilia therapeutics market

We provide a detailed analysis of around 25 vendors operating in the global hemophilia therapeutics market, including some of the vendors such as Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, Swedish Orphan Biovitrum AB and Takeda Pharmaceutical Co. Ltd. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/hemophilia-therapeutics-market-industry-analysis

About Technavio
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【レポートの目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five Forces Summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Type
o Market segments
o Comparison by Type placement
o Hemophilia A – Market size and forecast 2019-2024
o Hemophilia B – Market size and forecast 2019-2024
o Hemophilia C – Market size and forecast 2019-2024
o Market opportunity by Type
• Customer landscape
o Overview
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
• Drivers, Challenges, and Trends
o Market drivers
o Volume driver – Demand led growth
o Volume driver – Supply led growth
o Volume driver – External factors
o Volume driver – Demand shift in adjacent markets
o Price driver – Inflation
o Price driver – Shift from lower to higher priced units
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Bayer AG
o CSL Ltd.
o F. Hoffmann-La Roche Ltd.
o Grifols SA
o Novo Nordisk AS
o Octapharma AG
o Pfizer Inc.
o Sanofi
o Swedish Orphan Biovitrum AB
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
• Exhibits
• 1.Key Finding 1
• 2.Key Finding 2
• 3.Key Finding 3
• 4.Key Finding 4
• 5.Key Finding 5
• 6.Key Finding 6
• 7.Key Finding 7
• 8.Market in focus
• 9.Parent market
• 10.Market characteristics
• 11.Product / Service portfolio of key vendors included in the market definition
• 12.Market segments
• 13.Global – Market size and forecast 2019 – 2024 ($ billion)
• 14.Global market: Year-over-year growth 2019 – 2024 (%)
• 15.Five forces analysis 2019 & 2024
• 16.Bargaining power of buyers
• 17.Bargaining power of suppliers
• 18.Threat of new entrants
• 19.Threat of substitutes
• 20.Threat of rivalry
• 21.Market condition – Five forces 2019
• 22.Type placement – Market share 2019-2024 (%)
• 23.Comparison by Type placement
• 24.Hemophilia A – Market size and forecast 2019-2024 ($ billion)
• 25.Hemophilia A – Year-over-year growth 2019-2024 (%)
• 26.Hemophilia B – Market size and forecast 2019-2024 ($ billion)
• 27.Hemophilia B – Year-over-year growth 2019-2024 (%)
• 28.Hemophilia C – Market size and forecast 2019-2024 ($ billion)
• 29.Hemophilia C – Year-over-year growth 2019-2024 (%)
• 30. Market opportunity by Type
• 31.Customer landscape
• 32.Market share by geography 2019-2024 (%)
• 33.Geographic comparison
• 34.North America – Market size and forecast 2019-2024 ($ billion)
• 35.North America – Year-over-year growth 2019-2024 (%)
• 36.Europe – Market size and forecast 2019-2024 ($ billion)
• 37.Europe – Year-over-year growth 2019-2024 (%)
• 38.Asia – Market size and forecast 2019-2024 ($ billion)
• 39.Asia – Year-over-year growth 2019-2024 (%)
• 40.ROW – Market size and forecast 2019-2024 ($ billion)
• 41.ROW – Year-over-year growth 2019-2024 (%)
• 42.Key leading countries
• 43.Market opportunity by geography ($ billion)
• 44.Impact of drivers
• 45.Impact of challenges
• 46.Landscape disruption
• 47.Industry risks
• 48.Vendors covered
• 49.Market positioning of vendors
• 50.Bayer AG – Overview (1/3)
• 51.Bayer AG – Overview (2/3)
• 52.Bayer AG – Overview (3/3)
• 53.Bayer AG – Business segments
• 54.Bayer AG – Key offerings
• 55.Bayer AG – Key customers
• 56.Bayer AG – Segment focus
• 57.CSL Ltd. – Overview (1/3)
• 58.CSL Ltd. – Overview (2/3)
• 59.CSL Ltd. – Overview (3/3)
• 60.CSL Ltd. – Business segments
• 61.CSL Ltd. – Key offerings
• 62.CSL Ltd. – Key customers
• 63.CSL Ltd. – Segment focus
• 64.F. Hoffmann-La Roche Ltd. – Overview (1/3)
• 65.F. Hoffmann-La Roche Ltd. – Overview (2/3)
• 66.F. Hoffmann-La Roche Ltd. – Overview (3/3)
• 67.F. Hoffmann-La Roche Ltd. – Business segments
• 68.F. Hoffmann-La Roche Ltd. – Key offerings
• 69.F. Hoffmann-La Roche Ltd. – Key customers
• 70.F. Hoffmann-La Roche Ltd. – Segment focus
• 71.Grifols SA – Overview (1/3)
• 72.Grifols SA – Overview (2/3)
• 73.Grifols SA – Overview (3/3)
• 74.Grifols SA – Business segments
• 75.Grifols SA – Key offerings
• 76.Grifols SA – Key customers
• 77.Grifols SA – Segment focus
• 78.Novo Nordisk AS – Overview (1/3)
• 79.Novo Nordisk AS – Overview (2/3)
• 80.Novo Nordisk AS – Overview (3/3)
• 81.Novo Nordisk AS – Business segments
• 82.Novo Nordisk AS – Key offerings
• 83.Novo Nordisk AS – Key customers
• 84.Novo Nordisk AS – Segment focus
• 85.Octapharma AG – Overview (1/3)
• 86.Octapharma AG – Overview (2/3)
• 87.Octapharma AG – Overview (3/3)
• 88.Octapharma AG – Business segments
• 89.Octapharma AG – Key offerings
• 90.Octapharma AG – Key customers
• 91.Octapharma AG – Segment focus
• 92.Pfizer Inc. – Overview (1/3)
• 93.Pfizer Inc. – Overview (2/3)
• 94.Pfizer Inc. – Overview (3/3)
• 95.Pfizer Inc. – Business segments
• 96.Pfizer Inc. – Key offerings
• 97.Pfizer Inc. – Key customers
• 98.Pfizer Inc. – Segment focus
• 99.Sanofi – Overview (1/3)
• 100.Sanofi – Overview (2/3)
• 101.Sanofi – Overview (3/3)
• 102.Sanofi – Business segments
• 103.Sanofi – Key offerings
• 104.Sanofi – Key customers
• 105.Sanofi – Segment focus
• 106.Swedish Orphan Biovitrum AB – Overview (1/3)
• 107.Swedish Orphan Biovitrum AB – Overview (2/3)
• 108.Swedish Orphan Biovitrum AB – Overview (3/3)
• 109.Swedish Orphan Biovitrum AB – Business segments
• 110.Swedish Orphan Biovitrum AB – Key offerings
• 111.Swedish Orphan Biovitrum AB – Key customers
• 112.Swedish Orphan Biovitrum AB – Segment focus
• 113.Takeda Pharmaceutical Co. Ltd. – Overview (1/3)
• 114.Takeda Pharmaceutical Co. Ltd. – Overview (2/3)
• 115.Takeda Pharmaceutical Co. Ltd. – Overview (3/3)
• 116.Takeda Pharmaceutical Co. Ltd. – Business segments
• 117.Takeda Pharmaceutical Co. Ltd. – Key offerings
• 118.Takeda Pharmaceutical Co. Ltd. – Key customers
• 119.Takeda Pharmaceutical Co. Ltd. – Segment focus
• 120.Currency conversion rates for US$
• 121.Research Methodology
• 122.Validation techniques employed for market sizing
• 123.Information sources
• 124.List of abbreviations



【掲載企業】

Bayer AG
CSL Ltd.
F. Hoffmann-La Roche Ltd.
Grifols SA
Novo Nordisk AS
Octapharma AG
Pfizer Inc.
Sanofi
Swedish Orphan Biovitrum AB
Takeda Pharmaceutical Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[血友病治療薬の世界市場:種類別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆